Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy
Approval represents the first indication in the U.S. for TEVIMBRA
(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 061…